Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acceleron Pharma (XLRN) Misses Q2 EPS by 14c
August 3, 2017 4:13 PM EDTAcceleron Pharma (NASDAQ: XLRN) reported Q2 EPS of ($0.77), $0.14 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $3.69 million.
For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.
... More